This new report provides insights into Extra-label Drug Use (ELDU), its application in the veterinary setting and other guidelines and regulations followed by professionals in the animal health industry. Through a series of in-depth case studies this report provides insights into the rationale for the transition of several human drugs to the veterinary setting as well as disease overviews, competing treatments, manufacturer information, dosage forms, cost of therapy and other insightful marketing information. Our new study also identifies and explores important drivers and restraints of the crossover drugs market.
Information leveraged from our robust industry-leading database shows a diverse range of marketed human drugs being used in companion animals especially cats, dogs and horses. Our new report includes detailed profiles of key animal health companies with diverse portfolios of crossover drugs as well as strategies being employed by competitors in this market to leverage human therapies into the veterinary space. Additionally, we identify emerging companies marketing various crossover drugs across a range of therapy areas.
We conducted extensive research in order to provide a comprehensive view of the current trends and commercial prospects for crossover drugs. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising commercial areas in the market and exploit key business opportunities.
What regulations need to be followed when prescribing human drugs off-label to pets and food-producing animals?
What are the main factors driving the prescription of human medicines in animals?
Marketed human drugs commonly used in companion animals
- What are the differences in indication between the human and veterinary setting?
- What are the dosage and side effects of those specific drugs in animals?
- Are there any existing and approved veterinary therapies for the same indication? Why is the human drug preferred over the approved animal drug?
- What are the key drivers and barriers that affect ELDU of human drugs in animals?
- What is currently restricting the crossover drugs market?
- What are the key animal health companies with prominent crossover drug portfolios?
Explore recent financial performance, crossover drugs brands, and the number of species supported through their animal health product portfolio
Identify emerging companies in the animal health market investigating and marketing crossover drugs
Key Reasons to Purchase
This report will allow you to -
- Gain insightful analyses and understanding of the crossover drugs market: This report describes and assesses the key differences between the human and animal healthcare markets, areas of unmet need in the veterinary market and key factors responsible for ELDU in the veterinary setting.
- Assess high-profile marketed human products used for treating animals: Our new study provides analyses of the key human therapies that have the potential to be transitioned in the veterinary space.
- Identify the most important drivers and restraints of the crossover drugs market: This report provides insights regarding what is currently driving the prescription and application of human drugs in the veterinary setting as well as the current factors restraining further transition.
- Review the key and emerging companies that market crossover drugs and the business strategies being employed: This report assesses current tactics used by top veterinary pharmaceutical companies in manufacturing and marketing cross-over drugs. It also reviews the emerging companies that manufacture cross-over drugs for various indications.
- Assess future trends in the veterinary market: This report contains our prediction for what the future holds for crossover drugs, future treatment landscapes and evolving marketing models.
- The Human and Animal Healthcare Industries
- Human Drugs for Veterinary Use: Overview Regulations for Human Drugs Applied in Veterinary Medicine
- Regulation of Human Drugs for Veterinary Use in the US
- Extra-Label Drug Use Algorithm
- Regulation of Human Drugs for Veterinary Use in Canada
- Regulation of Human Drugs for Veterinary Use in the EU Unmet Needs and Factors Promoting Demand for Human Drugs in the Veterinary Space Human Drugs Applied in Veterinary Medicine: Case Studies
- Lysodren (Mitotane) in Dogs
- Fluoxetine hydrochloride (Prozac) in Dogs and Cats
- Benazepril (Lotensin, Fortekor) in Dogs and Cats
- Quinidine Sulfate in Horses and Dogs
- Chemotherapy in Dogs and Cats Human Drugs for Veterinary Use: Key Marketed Products
- Humulin N
- Human Prescription and OTC Drugs used in Dogs and Cats Factors Driving the Crossover Drugs Market Factors Restraining the Crossover Drugs Market Key Established Global Players in the Crossover Drugs Market
- Boehringer Ingelheim Vetmedica
- Merck/MSD Animal Health
- Elanco (Eli Lilly)
- Merial (Sanofi)
Our latest report states that the most significant drivers of Extralabel Drug Use (ELDU) in animals are financial. Unlike the human drugs market, veterinary clinics are involved not only in diagnosis and treatment, but also have the right to dispense pet medications. Consumers cannot purchase the prescribed medications from a pharmacy of their choice, where there would be access to low-priced generic drugs, and human treatments may be a viable alternative.
One of our analysts says: “A blockbuster drug in human health generates revenues in excess of $1 billion, whereas the animal health market’s highest selling drugs achieve $50-100 million, with around 85% of animal sales reaching less than $1 million. In this way, many manufacturers of veterinary drugs are looking for products already licensed for human use to fill their pipelines.”
Despite these drivers, there are safety, legal, ethical, and health issues associated with ELDU in animals. For instance, prescribing a human drug for veterinary use has its own risks. Mammalian species share many basic similarities in terms of responses to drugs, but there are differences seen at the cellular level, meaning responses may differ.
Another possibility might be that a human drug is prescribed despite the presence of a veterinary-approved alternative due to affordability issues, meaning a veterinarian could face legal issues.
This report provides details of Extra-label Drug Use (ELDU), its application in the veterinary setting and other guidelines and regulations followed by professionals in the animal health industry. It includes insights into the rationale for the transition of several human drugs to the veterinary setting as well as disease overviews, competing treatments, manufacturer information, dosage forms, cost of therapy and marketing information.